Appili Therapeutics Inc. (OTCMKTS:APLIF) Short Interest Update

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 7,800 shares, a growth of 310.5% from the October 15th total of 1,900 shares. Based on an average daily trading volume, of 290,100 shares, the short-interest ratio is presently 0.0 days.

Appili Therapeutics Stock Performance

Shares of OTCMKTS APLIF opened at $0.03 on Wednesday. The stock has a fifty day simple moving average of $0.02 and a two-hundred day simple moving average of $0.03. Appili Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.05. The firm has a market cap of $3.08 million, a price-to-earnings ratio of -0.85 and a beta of -0.49.

Appili Therapeutics (OTCMKTS:APLIF) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01).

About Appili Therapeutics

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.